products

Opzelura (generic name ruxolitinib cream 1.5%) is a prescription topical medication. It is the first topical Janus kinase (JAK) inhibitor approved for certain skin conditions. JAK inhibitors modulate the immune response by blocking JAK1/JAK2 enzymes, which in turn reduces inflammatory signals​. Opzelura comes as a cream applied to the skin.

What it’s used for: Opzelura is approved to treat:

In recent years, the global community has placed a greater emphasis on embracing diversity and inclusivity. This is reflected in the media, entertainment, education, and other spheres of life. With this mindset shift, it has become important to teach young children the value of inclusion and respect for diversity. One way to achieve this is through representation of people with visible differences.